AstraZeneca Oncology Advances Gain Momentum With New Cancer Approvals In Focus [Yahoo! Finance]
AstraZeneca PLC Ordinary Shares (AZN)
Last astrazeneca plc ordinary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Yahoo! Finance
The FDA has accepted and granted Priority Review for DATROWAY, co-developed by AstraZeneca (LSE:AZN) and Daiichi Sankyo, as a first-line treatment for certain patients with metastatic triple-negative breast cancer. The Priority Review is based on Phase III data and focuses on patients with limited treatment options in a hard to treat breast cancer subtype. Separately, the EU Committee for Medicinal Products for Human Use has recommended Imfinzi for approval as a perioperative treatment in early-stage and locally advanced gastric and gastroesophageal cancers. The EU recommendation for Imfinzi is supported by survival outcomes from the MATTERHORN trial in gastric and gastroesophageal cancer. AstraZeneca, traded as LSE:AZN, has put oncology at the center of its pharmaceutical portfolio, with a focus on targeted therapies and immuno-oncology. These new regulatory steps in breast and gastric cancers extend that focus into areas where patients often have few effective options. For
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC Ordinary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- AstraZeneca (NASDAQ:AZN) had its "sell" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.MarketBeat
- Shell chief exec to become one of FTSE's best paid bosses [Yahoo! Finance]Yahoo! Finance
- Why pharma manufacturers are still investing in Europe [Yahoo! Finance]Yahoo! Finance
- IonQ to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 [Yahoo! Finance]Yahoo! Finance
- Why Astrazeneca (AZN) Dipped More Than Broader Market Today [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 2/3/26 - Form S-8
- 2/3/26 - Form 6-K
- 2/2/26 - Form 6-K
- AZN's page on the SEC website